Abstracts tagged "autoantibodies"

Abstract Number: 37 • 2017 ACR/ARHP Annual Meeting
β2-Glycoprotein I Binds to Necroptotic Cells and Serves As a Target for SLE Autoantibodies
David Salem¹, Rebecca Subang¹, Maziar Divangahi¹, Christian Pineau², Sasha Bernatsky³, Jerrold S. Levine⁴ and Joyce Rauch⁵, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ³Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Section of Nephrology, Department of Medicine, University of Illinois at Chicago and Jesse Brown Veterans Affairs Medical Center, Chicago, IL, ⁵Division of Rheumatology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: β2-glycoprotein I (β2GPI), a phospholipid-binding protein, binds to apoptotic cells and serves as an antigenic target for autoantibodies from patients with systemic lupus erythematosus…
Abstract Number: 853 • 2017 ACR/ARHP Annual Meeting
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies
Alexander Oldroyd^1,2, Jamie C Sergeant^1,3, Paul New⁴, Neil J. McHugh^5,6, Zoe Betteridge⁵, Janine Lamb⁷, William Ollier⁷, Robert Cooper^4,7,8 and Hector Chinoy^2,9, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester, United Kingdom, ³Centre for Biostatistics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴MRC/ARUK Centre for Integrated Research into Musculoskeletal Ageing, University of Liverpool, Liverpool, United Kingdom, ⁵Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom, ⁷Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁸Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ⁹Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom
Background/Purpose: There is an increased cancer risk associated with the idiopathic inflammatory myopathies (IIM). Studies have identified that positivity for the autoantibody against transcriptional intermediary…
Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Javier Rangel-Moreno¹, Jennifer Barnard², Shelton Cochran³, Margaret Lee³, Sharon Tamir³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…
Abstract Number: 2814 • 2017 ACR/ARHP Annual Meeting
Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Jun Li⁶, Ignacio Sanz⁷, W. Winn Chatham⁸, Hui-Chen Hsu² and John D. Mountz⁹, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ⁸Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Department of Medicine, Birmingham, AL
Background/Purpose: Plasmacytoid dendritic cells are considered the main source of pathogenic IFN in SLE. However, recent work found that elevated serum type I IFN protein…
Abstract Number: 39 • 2017 ACR/ARHP Annual Meeting
Protein Array Technology Identifies Rituximab-Treated Non-Responder Rheumatoid Arthritis Patients to Generate New Autoantibody Repertoires during Treatment
Zoltán Konthur¹, Melvin Michael Wiemkes², Thomas Häupl², Gerd R. Burmester² and Karl Skriner², ¹Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann-Rheum-Dis. 2005 Feb;64(2):246-52)…
Abstract Number: 875 • 2017 ACR/ARHP Annual Meeting
Serum Autoantibody Profiling of Primary Sjoegren’s Syndrome Patients Reveals Novel Biomarkers Associated with the Disease, Disease Activity, and Clinical Response to VAY736
Petra Budde¹, Julie Doucet², Hans-Dieter Zucht¹, Remi Kazma², Paul Maguire², Alexandre Avrameas², Marie-Anne Valentin², Stephen Oliver², Peter Schulz-Knappe¹ and Alessandra Vitaliti², ¹Protagen AG, Dortmund, Germany, ²Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland
Background/Purpose: Overexpression of B cell activating factor (BAFF) in salivary glands contributes to the pathogenesis of primary Sjögren’s syndrome (pSS) by promoting autoantibody (AAB) production.…
Abstract Number: 1842 • 2017 ACR/ARHP Annual Meeting
Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity
Michelle Petri¹, Steven Watts², Richard Higgs², MaryAnn Morgan-Cox² and Matthew D Linnik³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Personalized therapy in systemic lupus erythematosus (SLE) will require identifying SLE subsets that will benefit from different targeted therapies. Belimumab, for example, has…
Abstract Number: 2815 • 2017 ACR/ARHP Annual Meeting
Pathological Roles By Siglec and Type I Interferons for the Development of Autoimmune Congenital Heart Block
Robert M. Clancy¹, Marc Halushka² and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Given that diseases associated with anti-SSA/Ro such as SLE and Sjögren’s syndrome associate with an upregulation of type I interferons, recent attention has focused…
Abstract Number: 44 • 2017 ACR/ARHP Annual Meeting
Characterization of Novel Stromal-Derived Autoantigens Recognized By RA Synovial Monoclonal Antibodies
Elisa Corsiero¹, Lucas Jagemann¹, Costantino Pitzalis² and Michele Bombardieri³, ¹Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
Background/Purpose: We previously showed that up to 40% of RA synovial recombinant monoclonal antibodies (RA-rmAbs) generated from germinal center-like structure (GC-LS+) RA synovium recognize citrullinated…
Abstract Number: 941 • 2017 ACR/ARHP Annual Meeting
Ro/SSA Autoantibody Exposed Neonates Have an Expansion of NK Cells and a Discernible Type II IFN Signature with High IFNγ in Peripheral Blood
Margarita Ivanchenko¹, Malin Hedlund¹, Gudny Ella Thorlacius¹, Vijole Ottosson¹, Karine Chemin², Sven-Erik Sonesson³ and Marie Wahren-Herlenius¹, ¹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Pediatric Cardiology Unit, Department of Women´s and Children´s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Congenital heart block (CHB) may develop in the fetus of women with Ro/SSA autoantibodies. The mothers are commonly diagnosed with Sjögren’s syndrome or SLE.…
Abstract Number: 1969 • 2017 ACR/ARHP Annual Meeting
Prevalence and Predictive Value over 16 Years of Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies in the General Population
Elena Generali¹, Natasa Isailovic¹, Maria De Santis¹, Angela Ceribelli¹, Fausto Alborghetti², Guido Colloredo³, Luisa Porrati², Torsten Matthias⁴, Alberto Zucchi², Giacomo Maria Guidelli¹, Marta Caprioli¹ and Carlo Selmi^1,5, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ²Bergamo Local Health Authority (ASL), Bergamo, Italy, ³Division of Internal Medicine, San Pietro Hospital, Ponte San Pietro (BG), Italy, ⁴Aesku.Diagnostics, Wendelsheim, Germany, ⁵BIOMETRA Department, University of Milan, Milan, Italy
Background/Purpose: The prevalence of Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies in the general population may vary widely, as RF is present in…
Abstract Number: 2817 • 2017 ACR/ARHP Annual Meeting
Expression Patterns of Interferon Induced Genes in Newborns Exposed to Ro/SSA Autoantibodies in Utero
Gudny Ella Thorlacius¹, Malin Hedlund¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Lars Rönnblom², Sven-Erik Sonesson³, Maija-Leena Eloranta⁴ and Marie Wahren-Herlenius¹, ¹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ³Pediatric Cardiology Unit, Department of Women´s and Children´s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁴Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden
Background/Purpose: Women with Sjögren’s syndrome and autoantibodies against Ro/SSA are at risk for pregnancy complications, including neonatal lupus erythematosus (NLE) and a congenital heart block…
Abstract Number: 84 • 2017 Pediatric Rheumatology Symposium
Predictors of Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, William Warren-Hicks², Michael Ward³, Nastaran Bayat¹, Lan Wu¹, Gulnara Mamyrova⁴, Ira N. Targoff⁵, Frederick Miller¹, Lisa G. Rider¹ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ²EcoStat, Inc., Mebane, NC, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Factors affecting treatment (Rx) responses in juvenile dermatomyositis (JDM) are not well understood. We examined a large JDM registry for predictors of excellent Rx…
Abstract Number: 16 • 2017 Pediatric Rheumatology Symposium
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G. Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…

« Previous Page
1
…
8
9
10
11
12
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].